

SpineGuard highlights its strategy in Shareholder Letter before Annual General Meeting

PARIS and **SAN FRANCISCO**, May **20**, **2019** – **18h00 CEST** – SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG® real time digital technology for surgical guidance intended to secure and streamline skeletal implant placement, announced today the publication of its Shareholder Letter to highlight its strategy before Annual General Meeting to be held on May 23, 2019.

The letter to shareholders is available on SpineGuard's website: http://www.spineguard.com/company/newsroom/press-releases/

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary real-time digital technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 70,000 surgical procedures worldwide. Fourteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG® was coinvented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard

Stéphane Bette Chief Executive Officer Tel: +33 (0) 1 45 18 45 19 s.bette@spineguard.com

Manuel Lanfossi Chief Financial Officer Tel: +33 (0)1 45 18 45 19 m.lanfossi@spineguard.com

NewCap

Investor Relations & Financial Communication Mathilde Bohin / Pierre Laurent Tel: +33 (0)1 44 71 94 94 spineguard@newcap.eu



